Toru Nakanishi

Aichi Cancer Center

Papers

1

Total Citations

5

H-Index

1

About

Toru Nakanishi is a leading figure in gynecologic oncology, with a focused expertise in the surgical management of uterine cervical cancer. His primary research area is the development and validation of less invasive surgical techniques for early-stage disease, aiming to reduce patient morbidity without compromising oncologic safety. Nakanishi’s major contribution is his leadership in the Japan Clinical Oncology Group study, JCOG1101, a landmark confirmatory trial that rigorously evaluated modified radical hysterectomy for patients with FIGO stage IB1 cervical cancer with tumors ≤2 cm. This work, published in 2023, provides critical evidence supporting a shift away from the highly invasive standard Piver class III hysterectomy. While the paper is recent with 5 citations, its impact is foundational, representing a paradigm-shifting effort to establish a new standard of care. Nakanishi’s work is central to the ongoing global conversation about de-escalation of surgical radicality, balancing cure with quality of life. His research directly informs clinical guidelines and offers a promising, evidence-based path toward safer, more patient-centered treatment for early cervical cancer.

Research Focus

Key Achievements

1
H-Index
1
Papers
5
Total Citations
5
Avg Citations/Paper
🏆 Most Cited Paper
A confirmatory trial of modified radical hysterectomy for patients with FIGO stage IB1 cervical cancer with tumor diameter preoperatively estimated at 2 cm or less: Japan Clinical Oncology Group study, JCOG1101.
5 citations · 2023
📈 Most Prolific Year: 2023 (1 Papers)
🤝 Key Collaborators: 19
🏛 Institutions: Aichi Cancer Center

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 13 days ago